Procedural Background

Plaintiff Komipharm International Co., Ltd., a Korean company, sues Sang Bong Lee based on allegations that Lee is not entitled to patent rights or profits from an arsenic-based anticancer drug.

On July 14, 2009, Komipharm filed a complaint against Bissox Incorporated, Lee, Dean Y. Park, Steve Han, and Bryan Kim for UCL violations, misappropriation of trade secrets, conversion, and aiding and abetting.

On September 3, 2010, upon stipulation of the parties that there was pending litigation in South Korea regarding the same issues, the Court (Judge Murphy) ordered the case stayed. The stay was lifted on December 15, 2016.

On August 25, 2017, Komipharm dismissed defendants Han and Kim with prejudice.

On March 1, 2018, the Court (Judge Shaller) granted Komipharm leave to file a First Amended Cross-Complaint (FACC).

The operative FACC was filed on March 27, 2018 and alleges three ........